Jennifer K Simpson, Ph.D., MSN, CRNP
President and Chief Executive Officer
Dr. Simpson joined Panbela as President and Chief Executive Officer in July of 2020 and was also appointed as a Director at that time. She brings to the Company more than 12 years’ experience in pharmaceutical executive leadership, global marketing and product commercialization. Most recently Dr. Simpson was the CEO of Delcath (Nasdaq:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancer.
She joined Delcath as Executive Vice President, Global Marketing in March 2012 and held various leadership positions there including interim President and CEO in 2014 until her promotion to CEO in 2015. From 2008 to 2012, Dr. Simpson served in various product leadership roles, including Vice President, Global Marketing, Oncology Brand Lead at ImClone Systems, Inc. (a wholly owned subsidiary of Eli Lilly and Company (NYSE:LLY)). From 2006 to 2008, Dr. Simpson held the position of Product Director, Oncology Therapeutics Marketing at Ortho Biotech (now Janssen Biotech), a biotechnology company focused on innovative solutions in immunology, oncology and nephrology. Earlier in her career, Dr. Simpson spent over a decade as a hematology/oncology nurse practitioner and educator. She has served on the Board of Directors and Nominating and Corporate Governance Committee of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) since 2019. Dr. Simpson earned a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo.
Vice President and Chief Financial Officer
Ms. Horvath has held both finance and operating positions within pharmaceutical, healthcare and consumer organizations. In addition to her position with the Company, Ms. Horvath sits on the board of directors and provides financial consulting services for Photonic Pharma, LLC, a privately held company focused on efficiencies in early stage drug discovery. Most recently she served as Chief Financial Officer of Eyebobs, LLC, a private company focused on the reading glasses industry.
Prior to that, Ms. Horvath was Vice President and Chief Financial Officer of Tenacious Holdings, Inc., a privately held safety products company that designed, manufactured and sold products to improve safety and productivity in the work place; Chief Financial Officer and Vice President of Human Resources at Healthsense, Inc., a next generation technology (SaaS) and remote monitoring company focused on providing safety and improving quality of life while reducing overall costs of healthcare for seniors and fragile adults; Chief Financial Officer, Vice President of Operations & Human Resources of Hemosphere, Inc., an early commercialization stage medical device company that manufactured and sold HeRO® – a clinically proven long-term vascular access device for hemodialysis patients; Director of Financial Planning & Analysis and Vice President & Team Leader International of CNS, Inc, a $140 million fast-growing consumer health care products company focused on the development and marketing of strong consumer brands, including Breathe Right® nasal strips, and FiberChoice® daily fiber supplements. Ms. Horvath holds a Bachelor of Science degree in Accounting from the University of Illinois, Champaign, and is a Certified Management Accountant and Certified Public Accountant, inactive.
Elizabeth Bruckheimer, Ph.D.
Vice President and Chief Scientific Officer
Dr. Elizabeth Bruckheimer joined Panbela as Vice President and Chief Scientific Officer in June 2022. Her professional career spans 20 years in oncology research, the biotech/pharmaceutical industry, and contract research organizations. In those endeavors, she led cross-functional preclinical/translational drug development programs, laboratory/organizational operations, regulatory affairs, project management, and business development activities.
Dr. Bruckheimer has been responsible for strategic and tactical pre- and post-approval plans in collaboration with clinical and commercial development teams, coordination of multiple programs from early drug candidate selection, regulatory submissions and interactions, to licensing drug development programs worldwide. From 2014-2022, Dr. Bruckheimer served as Vice President Drug Development and Regulatory Affairs at Cancer Prevention Pharmaceuticals leading and actively participating in all phases of planning, designing, and executing preclinical, translational, clinical pharmacology, clinical development, diagnostic/companion diagnostic projects including translational research, protocol development, and regulatory strategy, preparations, and interactions. Prior to joining Cancer Prevention Pharmaceuticals, Dr. Bruckheimer served as Vice President Scientific Operations at Champions Oncology, Associate Director and Manager at Systems Medicine, LLC., Senior Scientist at MedImmune, Inc., and Scientist II at Targeted Genetics Corporation where she led scientific operations, project management, pre-clinical and translational research programs, and supported business development opportunities for these organizations. She holds a B.S. in Biochemistry from the University of Arizona and a Ph.D. in Biomedical Sciences focusing on Molecular Pathology from the University of Texas Graduate School of Biomedical Sciences and M.D. Anderson Cancer Center in Houston Texas.
Ashok Chavan, Ph.D.
Vice President of CMC, Quality and Supply Chain
Dr. Chavan has extensive experience in pharmaceutical product development and product approval process with regulatory agencies having been involved in approval of Subsys, Syndros and Dronabinol Capsules. Prior to joining Panbela, Dr. Ashok served as VP of CMC, QA and Supply Chain for Cancer Prevention Pharmaceuticals from 2020 to 2022.
Rachel Bragg, MPH
Vice President of Clinical Development
Mrs. Bragg joined Panbela as Vice President of Clinical Development in June of 2021. She brings to the company ~20 years’ experience in pharmaceutical research which spans the biotech, pharma and CRO markets. Most recently Mrs. Bragg was the Therapeutic Area Head of Hematology Oncology for Product Delivery at PPD focusing on global program and trial strategy for various indications within hematology and oncology drug development.
During her career, Mrs. Bragg has received various excellence awards for performance and leadership. Of note an Extraordinary Effort Award for her leadership of the registrational trial for ramucirumab, a single agent or combination treatment for patients with gastric, HCC, NSCLC or mCRC. Mrs. Bragg has served as a Board Member and Board Committee Research Chair for the South Carolina Ovarian Cancer Foundation from 2015-2017. She also served as Team Captain for Susan G. Komen Greater NYC division from 2006-2010.
Mrs. Bragg earned a Master’s in Public Health as well as her Bachelor’s in Health Management. She also received a Lean Six Sigma Yellow Belt certificate in 2017.
Vice President of Operations
Since April 2012, Ms. Groene has provided operational management and administrative support to the Panbela team. Prior to joining Panbela Therapeutics, Inc., Ms. Groene worked for MGI Pharma, Inc. as the Executive Assistant to the Chief Medical Officer then transitioned into the Marketing Department. Ms. Groene earned her Bachelor of Science degree from St. Cloud State University in St. Cloud, Minnesota.
Anthony L. Kiorpes, Ph.D., DVM
Andy Kiorpes is a graduate of Columbia University (BA Biology, 1970), the University of Wisconsin-Madison (MS Veterinary Science, 1974; PhD Physiology, 1977) Kansas State University (DVM, 1982), and the University of Arkansas (MBA, 1999). He has over 22 years of experience as a toxicologist working in food, pharmaceutical, and medical device development and safety.
Michael Walker, M.D.
Pancreatic Research Consultant
Dr. Michael Walker obtained his BS (Biochemistry) and MD degrees from the University of Minnesota. He completed his General Surgery residency and a 2-year American Cancer Society clinical and research fellowship at UCLA, focusing on pancreatic islets and their molecular physiology. Before joining Panbela, he practiced General Surgery in Minnesota.